Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

Vicente Valero; John Forbes; Mark D Pegram; Tadeusz Pienkowski; Wolfgang Eiermann; Gunter von Minckwitz; Henri Roche; Miguel Martin; John Crown; John R Mackey; Pierre Fumoleau; Janusz Rolski; Zrinka Mrsic-Krmpotic; Agnieszka Jagiello-Gruszfeld; Alessandro Riva; Marc Buyse; Henry Taupin; Guido Sauter; Michael F Press; Dennis J Slamon

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

Standard

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. / Valero, Vicente; Forbes, John; Pegram, Mark D; Pienkowski, Tadeusz; Eiermann, Wolfgang; von Minckwitz, Gunter; Roche, Henri; Martin, Miguel; Crown, John; Mackey, John R; Fumoleau, Pierre; Rolski, Janusz; Mrsic-Krmpotic, Zrinka; Jagiello-Gruszfeld, Agnieszka; Riva, Alessandro; Buyse, Marc; Taupin, Henry; Sauter, Guido; Press, Michael F; Slamon, Dennis J.

in: J CLIN ONCOL, Jahrgang 29, Nr. 2, 2, 2011, S. 149-156.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Valero, V, Forbes, J, Pegram, MD, Pienkowski, T, Eiermann, W, von Minckwitz, G, Roche, H, Martin, M, Crown, J, Mackey, JR, Fumoleau, P, Rolski, J, Mrsic-Krmpotic, Z, Jagiello-Gruszfeld, A, Riva, A, Buyse, M, Taupin, H, Sauter, G, Press, MF & Slamon, DJ 2011, 'Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.', J CLIN ONCOL, Jg. 29, Nr. 2, 2, S. 149-156. <http://www.ncbi.nlm.nih.gov/pubmed/21115860?dopt=Citation>

APA

Valero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., von Minckwitz, G., Roche, H., Martin, M., Crown, J., Mackey, J. R., Fumoleau, P., Rolski, J., Mrsic-Krmpotic, Z., Jagiello-Gruszfeld, A., Riva, A., Buyse, M., Taupin, H., Sauter, G., Press, M. F., & Slamon, D. J. (2011). Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J CLIN ONCOL, 29(2), 149-156. [2]. http://www.ncbi.nlm.nih.gov/pubmed/21115860?dopt=Citation

Vancouver

Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J CLIN ONCOL. 2011;29(2):149-156. 2.

Bibtex

@article{b56354bea59143efa28419cc29ef1a58,

title = "Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.",

abstract = "Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC.",

keywords = "Humans, Female, Middle Aged, Disease-Free Survival, Neoplasm Metastasis, *Gene Amplification, Antibodies, Monoclonal, Humanized, Receptor, erbB-2/*genetics, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Antibodies, Monoclonal/administration & dosage/adverse effects, Breast Neoplasms/*drug therapy/*enzymology/genetics/pathology, Carboplatin/administration & dosage/adverse effects, Taxoids/administration & dosage/adverse effects, Humans, Female, Middle Aged, Disease-Free Survival, Neoplasm Metastasis, *Gene Amplification, Antibodies, Monoclonal, Humanized, Receptor, erbB-2/*genetics, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Antibodies, Monoclonal/administration & dosage/adverse effects, Breast Neoplasms/*drug therapy/*enzymology/genetics/pathology, Carboplatin/administration & dosage/adverse effects, Taxoids/administration & dosage/adverse effects",

author = "Vicente Valero and John Forbes and Pegram, {Mark D} and Tadeusz Pienkowski and Wolfgang Eiermann and {von Minckwitz}, Gunter and Henri Roche and Miguel Martin and John Crown and Mackey, {John R} and Pierre Fumoleau and Janusz Rolski and Zrinka Mrsic-Krmpotic and Agnieszka Jagiello-Gruszfeld and Alessandro Riva and Marc Buyse and Henry Taupin and Guido Sauter and Press, {Michael F} and Slamon, {Dennis J}",

year = "2011",

language = "English",

volume = "29",

pages = "149--156",

journal = "J CLIN ONCOL",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "2",

}

RIS

TY - JOUR

T1 - Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

AU - Valero, Vicente

AU - Forbes, John

AU - Pegram, Mark D

AU - Pienkowski, Tadeusz

AU - Eiermann, Wolfgang

AU - von Minckwitz, Gunter

AU - Roche, Henri

AU - Martin, Miguel

AU - Crown, John

AU - Mackey, John R

AU - Fumoleau, Pierre

AU - Rolski, Janusz

AU - Mrsic-Krmpotic, Zrinka

AU - Jagiello-Gruszfeld, Agnieszka

AU - Riva, Alessandro

AU - Buyse, Marc

AU - Taupin, Henry

AU - Sauter, Guido

AU - Press, Michael F

AU - Slamon, Dennis J

PY - 2011

Y1 - 2011

N2 - Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC.

AB - Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC.

KW - Humans

KW - Female

KW - Middle Aged

KW - Disease-Free Survival

KW - Neoplasm Metastasis

KW - Gene Amplification

KW - Antibodies, Monoclonal, Humanized

KW - Receptor, erbB-2/genetics

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use

KW - Antibodies, Monoclonal/administration & dosage/adverse effects

KW - Breast Neoplasms/drug therapy/enzymology/genetics/pathology

KW - Carboplatin/administration & dosage/adverse effects

KW - Taxoids/administration & dosage/adverse effects

KW - Humans

KW - Female

KW - Middle Aged

KW - Disease-Free Survival

KW - Neoplasm Metastasis

KW - Gene Amplification

KW - Antibodies, Monoclonal, Humanized

KW - Receptor, erbB-2/genetics

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use

KW - Antibodies, Monoclonal/administration & dosage/adverse effects

KW - Breast Neoplasms/drug therapy/enzymology/genetics/pathology

KW - Carboplatin/administration & dosage/adverse effects

KW - Taxoids/administration & dosage/adverse effects

M3 - SCORING: Journal article

VL - 29

SP - 149

EP - 156

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 2

M1 - 2

ER -